TY - JOUR
T1 - SAMe and sexual functioning
AU - Dording, C. M.
AU - Mischoulon, D.
AU - Shyu, I.
AU - Alpert, J. E.
AU - Papakostas, G. I.
N1 - Funding Information:
D.M. has received research support (usually as donated medications for clinical trials) from Laxdale (Amarin), Nordic Naturals and Ganeden; has served as an advisor/consultant for Bristol-Meyers Squibb Company; has received speaking and writing honoraria from Pamlab; has received royalties from Back Bay Scientific for PMS Escape (patent application pending), royalties from Lippincott Williams & Wilkins, for textbook “Natural Medications for Psychiatric Disorders: Considering the Alternatives” (David Mischoulon and Jerrold F Rosenbaum, Eds.); has received honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies cosupporting programs along with participant tuition. Commercial entities currently supporting the MGH Psychiatry Academy are listed on the Academy's website www.mghcme.org . No payment from any individual entity or company has exceeded $10,000/year.
PY - 2012/8
Y1 - 2012/8
N2 - Background: Sexual dysfunction is a known side effect of antidepressant treatment (ADT), affecting up to 58-73% of those who receive ADT, potentially affecting antidepressant adherence. Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction. Methods: We examined whether adjunctive S-adenosyl-l-methionine (SAMe) is associated with greater improvement in sexual functioning than adjunctive placebo by measuring changes in sexual functioning using the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) during a 6-week, single-center, randomized, double-blind trial of SAMe augmentation for SSRI/SNRI- nonresponders. Results: Controlling for the degree of arousal dysfunction at baseline as well as the degree of change in HDRS-17 scale scores during the course of the study, men treated with adjunctive SAMe demonstrated significantly lower arousal dysfunction at endpoint than those treated with adjunctive placebo. In addition, controlling for the degree of erectile dysfunction at baseline as well as the degree of change in HDRS-17 scale scores, men treated with adjunctive SAMe demonstrated significantly lower erectile dysfunction at endpoint than those treated with adjunctive placebo. Conclusions: In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms. These findings are preliminary, and warrant replication. Clinical trials.gov identifier: NCT00093847; titled 'Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression', accessible at: http://clinicaltrials.gov/ct2/show/. NCT00093847.
AB - Background: Sexual dysfunction is a known side effect of antidepressant treatment (ADT), affecting up to 58-73% of those who receive ADT, potentially affecting antidepressant adherence. Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction. Methods: We examined whether adjunctive S-adenosyl-l-methionine (SAMe) is associated with greater improvement in sexual functioning than adjunctive placebo by measuring changes in sexual functioning using the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) during a 6-week, single-center, randomized, double-blind trial of SAMe augmentation for SSRI/SNRI- nonresponders. Results: Controlling for the degree of arousal dysfunction at baseline as well as the degree of change in HDRS-17 scale scores during the course of the study, men treated with adjunctive SAMe demonstrated significantly lower arousal dysfunction at endpoint than those treated with adjunctive placebo. In addition, controlling for the degree of erectile dysfunction at baseline as well as the degree of change in HDRS-17 scale scores, men treated with adjunctive SAMe demonstrated significantly lower erectile dysfunction at endpoint than those treated with adjunctive placebo. Conclusions: In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms. These findings are preliminary, and warrant replication. Clinical trials.gov identifier: NCT00093847; titled 'Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression', accessible at: http://clinicaltrials.gov/ct2/show/. NCT00093847.
KW - Antidepressant-induced sexual dysfunction
KW - Antidepressants
KW - Major Depressive Disorder
KW - S-adenosyl methionine
KW - Side effects
UR - http://www.scopus.com/inward/record.url?scp=84863871164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863871164&partnerID=8YFLogxK
U2 - 10.1016/j.eurpsy.2011.01.003
DO - 10.1016/j.eurpsy.2011.01.003
M3 - Article
C2 - 21398094
AN - SCOPUS:84863871164
SN - 0924-9338
VL - 27
SP - 451
EP - 454
JO - European Psychiatry
JF - European Psychiatry
IS - 6
ER -